Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
38.60
+0.99 (2.63%)
At close: Sep 4, 2026, 4:00 PM EDT
38.12
-0.48 (-1.24%)
After-hours: Sep 4, 2026, 7:30 PM EDT
Neurogene Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
131
Market Cap
772.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| Phathom Pharmaceuticals | 239.66M |
| Verastem | 87.53M |
| Assembly Biosciences | 74.85M |
| DBV Technologies | 5.04M |
| Oculis Holding AG | 1.45M |
NGNE News
- 3 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Neurogene price target lowered to $65 from $70 at H.C. Wainwright - TheFly
- 21 days ago - Neurogene price target raised to $81 from $69 at Guggenheim - TheFly
- 21 days ago - Neurogene price target lowered to $166 from $180 at Canaccord - TheFly
- 27 days ago - Neurogene Slides: Corporate presentation - Filings
- 27 days ago - Neurogene reports Q2 EPS ($1.53), consensus ($1.38) - TheFly
- 27 days ago - Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates - Business Wire
- 27 days ago - Neurogene Earnings release: Q2 2026 - Filings